+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
TKI for Chronic Myeloid Leukemia Market by Molecule (Bosutinib, Dasatinib, Imatinib), Mechanism (First Generation, Second Generation, Third Generation), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
TKI for Chronic Myeloid Leukemia Market by Molecule (Bosutinib, Dasatinib, Imatinib), Mechanism (First Generation, Second Generation, Third Generation), Distribution Channel, End User - Global Forecast 2025-2030- Product Image
Sale

TKI for Chronic Myeloid Leukemia Market by Molecule (Bosutinib, Dasatinib, Imatinib), Mechanism (First Generation, Second Generation, Third Generation), Distribution Channel, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6079176
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Over the past two decades, targeted therapies have redefined the prognosis for patients diagnosed with chronic myeloid leukemia, shifting the narrative from terminal illness to manageable condition. Groundbreaking molecules such as imatinib inaugurated a new era of precision oncology, setting the benchmark for subsequent inhibitors. As the therapeutic arsenal expanded to include second-generation agents like dasatinib and nilotinib, followed by third-generation options such as bosutinib and ponatinib, physicians gained deeper control over disease progression, relapse prevention, and adverse event management. Consequently, life expectancy has improved, and quality of life has become a central metric of treatment success.

Building upon this foundation, the present study offers a holistic examination of the evolving landscape of tyrosine kinase inhibitors for chronic myeloid leukemia. It synthesizes regulatory developments, policy shifts, and competitive dynamics to provide a cohesive narrative. By integrating insights from clinical breakthroughs, payer considerations, and patient adherence trends, this analysis equips decision-makers with the context needed to navigate complexities and leverage emerging opportunities in this critical therapeutic field.

Unveiling the Next Frontier in Chronic Myeloid Leukemia Management as Generational Advances Redefine Treatment Efficacy and Patient Outcomes

The chronic myeloid leukemia landscape has undergone radical transformation as successive generations of inhibitors emerged to address resistance and tolerability issues. Initially, first-generation treatment demonstrated unprecedented efficacy, but a subset of patients experienced resistance driven by BCR-ABL mutations. In response, second-generation therapies offered enhanced potency and broader mutation coverage, significantly reducing the need for dose escalations and improving adverse event profiles. Moreover, the introduction of third-generation inhibitors addressed specific mutation variants resistant to earlier agents, thereby reinforcing the therapeutic continuum.

Alongside these pharmacological milestones, the treatment environment evolved through refined diagnostic algorithms and monitoring strategies. Advances in molecular assays now allow for real-time tracking of minimal residual disease, enabling practitioners to tailor dosing and switch therapies proactively. Regulatory agencies have expedited review pathways for breakthrough designations, fostering a climate of rapid innovation. Consequently, the interplay between clinical advances, regulatory agility, and patient-centric monitoring has ushered in a new frontier where therapeutic precision and adaptable care models converge to optimize outcomes.

Assessing How Emerging Tariff Policies Are Reshaping Access, Affordability, and Supply Chain Dynamics for Leukemia Therapies in the United States

The introduction of revised tariff policies in 2025 has exerted a tangible influence on the accessibility and distribution of leukemia therapies within domestic markets. Manufacturers face heightened scrutiny over import duties, compelling supply chain recalibrations and strategic sourcing decisions. Consequently, procurement cycles have lengthened as stakeholders reassess cost structures and negotiate with international suppliers to mitigate tariff-induced fluctuations. In parallel, distribution networks have adapted by diversifying regional warehousing and leveraging in-country manufacturing where feasible, ensuring continuity of supply despite evolving fiscal constraints.

Patient advocacy groups and healthcare providers have expressed concerns regarding potential downstream effects on treatment adherence and out-of-pocket burden. As payers reevaluate formulary placements, negotiation dynamics have shifted to balance clinical value with budgetary impact. Ultimately, the confluence of tariff adjustments and stakeholder responses underscores the critical importance of proactive policy engagement and agile operational strategies. By anticipating regulatory recalibrations and fostering transparent dialogue across the value chain, industry participants can maintain consistent access to essential therapies for those reliant on targeted leukemia treatments.

Delving into Multidimensional Market Segmentation to Reveal Tailored Insights on Molecules, Mechanisms, Distribution Channels, and End User Preferences

A nuanced understanding of chronic myeloid leukemia treatment patterns emerges when the market is dissected along complementary dimensions that capture therapeutic diversity and patient interaction points. Based on molecule, the field encompasses the pioneering agent imatinib alongside second-generation inhibitors nilotinib and dasatinib, as well as later entrants bosutinib and the highly specific ponatinib. Each molecular innovation brings unique pharmacokinetic properties and resistance profiles that inform clinical decision pathways.

When examined through the lens of mechanism, the progression from first-generation to third-generation therapies reflects a deliberate intensification of target binding and mutation coverage. This hierarchy allows clinicians to escalate treatment precisely in response to evolving disease biology. Moreover, integration across distribution channels ensures that these therapies reach patients in varied settings; hospital pharmacies remain a cornerstone for initial dosing and monitoring, while online pharmacies provide discreet delivery options that enhance convenience, and retail pharmacies facilitate broader community access.

Equally important is the end user perspective, where clinics serve as pivotal hubs for therapeutic initiation and adverse event management, home care settings support adherence through nursing support, and hospitals address complex cases requiring multidisciplinary coordination. Together, these segmentation insights offer a comprehensive framework for strategic planning and resource allocation.

Illuminating Regional Patterns in Therapeutic Adoption, Regulatory Frameworks, Investment Trends, and Treatment Accessibility across the Americas, EMEA, and Asia-Pacific

Regional nuances in chronic myeloid leukemia treatment adoption reflect a complex interplay of regulatory frameworks, healthcare infrastructure, and investment priorities. In the Americas, robust payer networks and early adoption of innovative therapies underscore a competitive environment where value-based agreements and real-world evidence drive formulary decisions. Clinicians benefit from extensive post-marketing surveillance data, informing best practice guidelines and enhancing patient outcomes.

Across Europe, the Middle East and Africa, diverse health systems present both challenges and opportunities. Stringent regulatory harmonization efforts within Europe facilitate cross-border collaboration, whereas variable reimbursement policies in emerging economies require adaptive pricing strategies. Patient advocacy initiatives are gaining momentum, advocating for equitable access and fostering public-private partnerships that expand treatment capacity.

In the Asia-Pacific region, government-led programs prioritize local manufacturing and biosimilar development to address affordability barriers. As a result, emerging markets demonstrate rapid uptake of cost-effective alternatives while simultaneously investing in advanced diagnostic capabilities. Strategic collaborations between multinational developers and regional stakeholders are increasingly common, promoting technology transfer and capacity-building initiatives that strengthen long-term treatment landscapes.

Profiling Pioneering Organizations Driving Innovation through Strategic Collaborations, Pipeline Diversification, and Differentiated Patient Support Programs

Leading pharmaceutical organizations continue to redefine competitive dynamics through targeted collaborations, portfolio diversification, and patient support innovations. Industry frontrunners have entered strategic alliances with biotechnology firms to expand pipeline breadth, securing early access to promising molecular entities that address resistant BCR-ABL mutations. Simultaneously, sustained investments in antibody-drug conjugate research and combination therapy trials illustrate a commitment to next-generation solutions.

In parallel, companies have enhanced patient engagement by deploying digital adherence tools and financial assistance programs, reinforcing treatment continuity and mitigating attrition. Moreover, differentiated manufacturing approaches, including continuous processing and modular facility designs, have optimized scale-up timelines and minimized supply disruptions. As a result, these organizations maintain agile production capabilities that align with fluctuating demand and evolving regulatory requirements.

Collectively, these strategic imperatives underscore the importance of balanced innovation and operational resilience. By harmonizing clinical advancement with scalable infrastructure and patient-centric services, industry leaders position themselves to navigate complex market dynamics and deliver sustainable value across the chronic myeloid leukemia treatment continuum.

Strategic Recommendations for Industry Leaders to Enhance Market Preparedness, Optimize Operational Efficiencies, and Accelerate Clinical Impact in Leukemia Care

To maintain competitive advantage and enhance treatment accessibility, stakeholders should engage proactively with newly enacted policy frameworks, participating in advisory committees and advocacy coalitions to shape equitable tariff structures. Concurrently, investment in local manufacturing or co-manufacturing partnerships can offset import duty pressures and reinforce supply security.

Moreover, integrating real-world data platforms into clinical development and post-approval monitoring will yield actionable insights on long-term efficacy and tolerability, informing adaptive dosing strategies and personalized care models. From an operational standpoint, optimizing logistics through advanced demand forecasting tools and regional distribution hubs will reduce lead times and minimize stockouts. In addition, enhancing digital patient engagement via telemedicine and remote monitoring solutions will strengthen adherence and broaden therapy reach in underserved communities.

By aligning strategic priorities with evolving market drivers, organizations can fortify their position across product lifecycles. These recommendations advocate for a holistic approach that balances regulatory navigation, data-driven decision-making, and patient-centric innovation to catalyze sustained growth in the chronic myeloid leukemia treatment arena.

Comprehensive Research Framework Combining Primary Interviews, Rigorous Secondary Analysis, and Quantitative Validation to Ensure Robust Market Intelligence

This analysis synthesizes insights derived from a multifaceted research framework that balances qualitative depth with quantitative rigor. Primary data sources include in-depth interviews with leading hematologists, policy experts, payer representatives, and supply chain executives, providing firsthand perspectives on clinical trends and regulatory landscapes. Secondary sources encompass peer-reviewed journals, regulatory filings, clinical trial registries, and real-world evidence databases, ensuring comprehensive coverage of therapeutic advancements and adoption patterns.

Data triangulation involved cross-validation of interview findings with published clinical outcomes and publicly available formulary decisions. Advanced analytical techniques, such as thematic coding and trend mapping, identified emergent patterns in resistance mutations, pricing negotiations, and patient adherence behaviors. Quantitative validation leveraged prescription and reimbursement datasets to corroborate qualitative insights and highlight regional variances.

Collectively, this methodological approach delivers robust, actionable intelligence that reflects the most current developments in chronic myeloid leukemia treatment. Rigorous quality assurance protocols, including peer review and expert validation, underpin the credibility of findings and ensure their relevance for strategic decision-making.

Concluding Perspectives on the Evolution of Targeted Therapy in Leukemia Emphasizing Critical Insights for Stakeholder Decision-Making and Future Directions

This executive summary has illuminated the transformative journey of targeted therapies in chronic myeloid leukemia, from the advent of first-generation inhibitors to the precision afforded by third-generation molecules. It has underscored the strategic implications of regulatory shifts, tariff policies, and regional nuances that collectively shape market dynamics and patient access. Moreover, segmentation insights clarified how molecule-specific properties, mechanism-based hierarchies, distribution pathways, and end-user environments coalesce to influence treatment uptake and continuation.

Key organizational strategies, including collaborative pipeline expansion and patient support innovations, further demonstrate how industry participants navigate competitive pressures and operational complexities. By adopting the recommended actions-ranging from proactive policy engagement and local manufacturing diversification to advanced data integration and digital patient engagement-leaders can enhance resilience and catalyze sustained growth. Ultimately, this synthesis of clinical, commercial, and operational perspectives equips stakeholders with the clarity needed to drive informed decisions in an evolving therapeutic landscape.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Molecule
    • Bosutinib
    • Dasatinib
    • Imatinib
    • Nilotinib
    • Ponatinib
  • Mechanism
    • First Generation
    • Second Generation
    • Third Generation
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User
    • Clinics
    • Home Care Settings
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Dr. Reddy’s Laboratories Limited
  • Mylan N.V.
  • Cipla Limited
  • Natco Pharma Limited

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of next generation BCR-ABL inhibitors with improved safety and potency profiles in CML treatment
5.2. Increasing use of digital health platforms and remote monitoring tools to optimize patient adherence and outcomes in chronic myeloid leukemia
5.3. Expansion of generic tyrosine kinase inhibitors leading to pricing pressures and formulary reshaping in CML therapy
5.4. Growth of combination therapies targeting leukemic stem cells to overcome resistance and achieve deeper molecular responses in CML
5.5. Advances in genomic profiling and minimal residual disease testing enabling personalized treatment adjustments for chronic myeloid leukemia
5.6. Integration of real world evidence and patient reported outcomes in regulatory submissions and reimbursement decisions for CML therapeutics
5.7. Increasing focus on treatment discontinuation strategies and treatment free remission criteria in long term CML management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. TKI for Chronic Myeloid Leukemia Market, by Molecule
8.1. Introduction
8.2. Bosutinib
8.3. Dasatinib
8.4. Imatinib
8.5. Nilotinib
8.6. Ponatinib
9. TKI for Chronic Myeloid Leukemia Market, by Mechanism
9.1. Introduction
9.2. First Generation
9.3. Second Generation
9.4. Third Generation
10. TKI for Chronic Myeloid Leukemia Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. TKI for Chronic Myeloid Leukemia Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Home Care Settings
11.4. Hospitals
12. Americas TKI for Chronic Myeloid Leukemia Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa TKI for Chronic Myeloid Leukemia Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific TKI for Chronic Myeloid Leukemia Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Novartis AG
15.3.2. Bristol-Myers Squibb Company
15.3.3. Takeda Pharmaceutical Company Limited
15.3.4. Pfizer Inc.
15.3.5. Sun Pharmaceutical Industries Limited
15.3.6. Teva Pharmaceutical Industries Limited
15.3.7. Dr. Reddy’s Laboratories Limited
15.3.8. Mylan N.V.
15.3.9. Cipla Limited
15.3.10. Natco Pharma Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET: RESEARCHAI
FIGURE 24. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET: RESEARCHSTATISTICS
FIGURE 25. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET: RESEARCHCONTACTS
FIGURE 26. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY BOSUTINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY BOSUTINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DASATINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DASATINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY IMATINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY IMATINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY NILOTINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY NILOTINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PONATINIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY PONATINIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 55. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 56. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 65. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 66. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 67. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 68. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 69. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. CANADA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 74. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 75. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 76. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 77. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 78. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 79. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. MEXICO TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 82. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 83. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 84. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 85. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 86. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 87. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. BRAZIL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 90. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 91. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 92. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 93. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. ARGENTINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 108. UNITED KINGDOM TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 110. UNITED KINGDOM TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. UNITED KINGDOM TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. UNITED KINGDOM TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 114. UNITED KINGDOM TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 115. GERMANY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 116. GERMANY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 117. GERMANY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 118. GERMANY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 119. GERMANY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. GERMANY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. GERMANY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. GERMANY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. FRANCE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 124. FRANCE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 125. FRANCE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 126. FRANCE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 127. FRANCE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 128. FRANCE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 129. FRANCE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. FRANCE TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. RUSSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 132. RUSSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 133. RUSSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 134. RUSSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 135. RUSSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. RUSSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. RUSSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. RUSSIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. ITALY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 140. ITALY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 141. ITALY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 142. ITALY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 143. ITALY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 144. ITALY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 145. ITALY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. ITALY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. SPAIN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 148. SPAIN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 149. SPAIN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 150. SPAIN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 151. SPAIN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. SPAIN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. SPAIN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. SPAIN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 164. SAUDI ARABIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 165. SAUDI ARABIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 166. SAUDI ARABIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. SAUDI ARABIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. SAUDI ARABIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 172. SOUTH AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 173. SOUTH AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 174. SOUTH AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. SOUTH AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. SOUTH AFRICA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. DENMARK TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 180. DENMARK TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 181. DENMARK TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 182. DENMARK TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 183. DENMARK TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. DENMARK TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. DENMARK TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. DENMARK TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. NETHERLANDS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 188. NETHERLANDS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 189. NETHERLANDS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 190. NETHERLANDS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 191. NETHERLANDS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. NETHERLANDS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. NETHERLANDS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 194. NETHERLANDS TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 195. QATAR TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 196. QATAR TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 197. QATAR TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 198. QATAR TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 199. QATAR TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 200. QATAR TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 201. QATAR TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. QATAR TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. FINLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 204. FINLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 205. FINLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 206. FINLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 207. FINLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 208. FINLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 209. FINLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 210. FINLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 211. SWEDEN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 212. SWEDEN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 213. SWEDEN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 214. SWEDEN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 215. SWEDEN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. SWEDEN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. SWEDEN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. SWEDEN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. NIGERIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 220. NIGERIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 221. NIGERIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 222. NIGERIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 223. NIGERIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. NIGERIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. NIGERIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. NIGERIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. EGYPT TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 228. EGYPT TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 229. EGYPT TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 230. EGYPT TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 231. EGYPT TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 232. EGYPT TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 233. EGYPT TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 234. EGYPT TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 235. TURKEY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 236. TURKEY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 237. TURKEY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 238. TURKEY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 239. TURKEY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. TURKEY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. TURKEY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. TURKEY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. ISRAEL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 244. ISRAEL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 245. ISRAEL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 246. ISRAEL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 247. ISRAEL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 248. ISRAEL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 249. ISRAEL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. ISRAEL TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. NORWAY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 252. NORWAY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 253. NORWAY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 254. NORWAY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 255. NORWAY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. NORWAY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. NORWAY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. NORWAY TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. POLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 260. POLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 261. POLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 262. POLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 263. POLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. POLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. POLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 266. POLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 267. SWITZERLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 268. SWITZERLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 269. SWITZERLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 270. SWITZERLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 271. SWITZERLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 272. SWITZERLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 273. SWITZERLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. SWITZERLAND TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 276. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 278. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 279. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 284. ASIA-PACIFIC TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 285. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 286. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 287. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 288. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 289. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 292. CHINA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 293. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 294. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 295. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 296. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 297. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 300. INDIA TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 301. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2018-2024 (USD MILLION)
TABLE 302. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MOLECULE, 2025-2030 (USD MILLION)
TABLE 303. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 304. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 305. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 306. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 307. JAPAN TKI FOR CHRONIC MYELOID LEUKEMIA MARKE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this TKI for Chronic Myeloid Leukemia market report include:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Dr. Reddy’s Laboratories Limited
  • Mylan N.V.
  • Cipla Limited
  • Natco Pharma Limited

Related Topics

Related Reports

Treating Chronic Myeloid Leukemia by Phase Market by Treatment Type (Chemotherapy, Stem Cell Transplantation, Tyrosine Kinase Inhibitor), Phase (Accelerated Phase, Blast Crisis, Chronic Phase), Treatment Setting, Patient Age Group - Global Forecast 2025-2030 - Product Image

Treating Chronic Myeloid Leukemia by Phase Market by Treatment Type (Chemotherapy, Stem Cell Transplantation, Tyrosine Kinase Inhibitor), Phase (Accelerated Phase, Blast Crisis, Chronic Phase), Treatment Setting, Patient Age Group - Global Forecast 2025-2030

  • Report
  • 195 Pages
  • Global
From
Leukemia Therapeutics Market by Type, Mechanism of Action, Line of Therapy, Route of Administration, Age Group, End-User - Global Forecast 2025-2030 - Product Image

Leukemia Therapeutics Market by Type, Mechanism of Action, Line of Therapy, Route of Administration, Age Group, End-User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Chronic Myeloid Leukemia - Pipeline Insight, 2025 - Product Image

Chronic Myeloid Leukemia - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Leukemia Therapeutics Market Report 2025 - Product Image

Leukemia Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Leukemia Therapeutics - Global Strategic Business Report - Product Image

Leukemia Therapeutics - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.